Telix Pharmaceuticals Limited · FWB:T3X

Telix Pharmaceuticals Limited financial statements

Telix Pharmaceuticals Limited's income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue803.8M516.6M333.0M160.1M7.60M5.21M3.48M195.1K403.5K0
Cost of revenue377.4M180.4M123.4M130.8M37.4M2.02M15.4M03.79K0
Gross profit426.4M336.2M209.5M29.3M-29.8M3.19M-11.9M195.1K-3.79K0
Research and development171.2M127.9M85.3M57.9M34.1M23.1M21.2M18.7M2.98M10.0K
Selling, general and administrative94.0M49.1M41.1M18.0M11.3M8.50M2.46M20.0K
Operating income29.8M55.2M11.0M-73.2M-81.2M-49.3M-40.3M-27.6M-6.52M-30.0K
Depreciation and amortization21.4M5.28M4.16M5.38M5.17M4.88M4.24M6.97K3.79K30.0K
EBITDA51.2M60.5M15.2M-67.8M-76.1M-44.4M-36.0M-27.6M-6.52M0
Interest expense181.0K64.0K97.0K406.0K189.0K1.18M2.41M29.0K9.40K0
Income before tax-5.27M37.9M2.59M-98.6M-99.0M-60.3M-42.8M-15.7M-6.38M-44.0K
Income tax1.86M4.23M-1.61M5.46M-18.5M-15.4M-14.9M-1.88M-403.5K-14.0K
Net income-7.13M33.7M4.21M-104.1M-80.5M-44.9M-27.9M-13.8M-6.38M-44.0K
Earnings per share, basic-0.020.100.01-0.34-0.29-0.17-0.12-0.07-0.05-0.00
Earnings per share, diluted-0.020.100.01

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents141.9M440.0M84.3M116.3M22.0M77.9M44.6M25.8M48.8M
Receivables129.2M86.9M44.0M45.9M20.8M14.2M13.0M8.44M488.8K
Inventory37.1M23.6M12.7M8.48M3.45M633.0K542.0K642.5K297.2K
Current assets330.3M570.1M158.7M173.2M47.5M93.6M58.7M35.9M49.5M
Property, plant and equipment58.7M27.8M15.8M18.8M6.33M4.82M1.90M226.0K5.39K
Goodwill199.0M66.6M5.52M4.10M4.22M4.22M3.14M332.5K
Total assets1.16B940.4M277.3M255.4M109.8M157.8M102.6M76.7M51.1M
Accounts payable150.3M86.8M54.3M16.8M11.9M5.81M6.96M3.25M275.8K
Current liabilities231.6M205.1M111.4M85.6M38.0M20.0M10.6M8.24M1.47M
Long-term debt391.9M341.8M5.95M3.31M095.0K292.0K596.3K
Total debt405.0M353.6M6.61M10.4M2.54M2.21M2.13M1.73M345.4K
Total liabilities748.6M587.4M174.6M175.3M106.2M78.8M32.5M23.8M1.80M
Shareholders' equity415.4M352.9M102.6M80.0M2.16M79.0M70.1M52.9M49.3M
Shares outstanding337.9M310.6M282.2M257.3M233.4M202.1M128.0M128.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-17.3M27.5M14.3M-64.0M-59.3M1.96M-23.3M-20.7M-6.03M-6.03M
Capital spending-25.7M-9.12M-6.31M-13.9M-1.34M-322.0K-468.0K-403.0K-5.64K-5.64K
Free cash flow-43.0M18.4M7.97M-77.8M-60.7M1.64M-23.8M-20.7M-6.04M-6.04M
Cash from investing-285.9M-86.7M-16.8M-17.0M-2.73M-1.09M-468.0K-2.69M-1.26K-1.26K
Cash from financing-3.72M416.8M7.09M175.0M2.85M34.1M42.7M-869.4K54.8M54.8M
Dividends paid-168.4M-34.5M-54.8M
Share buybacks1.81M-7.82M3.78M-130.0K45.3M0-2.99M58.6M
Change in cash-306.9M357.6M4.53M94.3M-55.9M33.3M18.8M-23.0M54.8M48.8M